A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

← catalyst calendar

NCT06782373 · readout in 133 d

Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With PSI CRO.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

78estimated

Sites

Countries

Canada, France, Germany +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-05-28

actual

When the study began enrolling

Primary completion

2026-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-05-22

estimated

The whole study's end, after follow-up

First posted

2025-01-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

VEXAS
VEXAS Syndrome

Interventions

Drug: Pacritinib
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period.

measured up to End of Week 24

Publications

PMID 41753113 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed